COLL COLLEGIUM PHARMACEUTICAL, INC

8-K Current Report

Filed: March 19, 2026

Health Care

Pharmaceutical Preparations

COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Collegium Pharma to acquire AZSTARYS ADHD drug for $650M cash plus up to $135M in regulatory/commercial milestone payments
• Acquisition targets GPC Commave Holding LLC and NewCo from Corium subsidiaries, expanding CNS stimulant portfolio

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Announcement of AZSTARYS® acquisition signals strategic expansion of COLLEGIUM's ADHD portfolio and commercial footprint
• Presentation and press release from March 19, 2026 provide details on acquisition rationale and expected financial impact

+3 more insights

Other COLLEGIUM PHARMACEUTICAL, INC 8-K Filings

8-K Feb 26, 2026

Get deeper insights on COLLEGIUM PHARMACEUTICAL, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.